Tumor suppressor genes associated with drug resistance in ovarian cancer (Review)

Oncology Reports

Volumn 30, Issue 1, 2013, Pages 3-10

  Yin, Fuqiang ^a   Liu, Xia ^a   Li, Danrong ^a   Wang, Qi ^a   Zhang, Wei ^a   Li, Li ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Drug resistance; Ovarian cancer; Tumor suppressor gene

Indexed keywords

ATROGIN 1; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CHECKPOINT KINASE 2; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH ASSOCIATED PROTEIN KINASE; INTERLEUKIN 24; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MLH1; PROTEIN P53; PROTEIN P73; TUMOR PROTEIN; TUMOR PROTEIN 63; UBIQUITIN C; UNCLASSIFIED DRUG;

ADENOMATOUS POLYP; APC GENE; APOPTOSIS; ASC GENE; BRCA2 GENE; CDKN1A GENE; CDKN2A GENE; CELL CYCLE; CHEK2 GENE; CHK2 GENE; DAPK GENE; DNA BINDING; DNA DAMAGE; DNA METHYLATION; DRUG RESISTANCE; FBXO32 GENE; FEMALE; GENE ACTIVITY; GENE FUNCTION; GENE INTERACTION; GENETIC ASSOCIATION; HUMAN; IL24 GENE; MDA 7 GENE; MLH1 GENE; OVARY CANCER; P16 GENE; P21 GENE; PDCD4 GENE; PLAGL1 GENE; PRIORITY JOURNAL; PTEN GENE; PYCARD GENE; RASSF1 GENE; RB1 GENE; REVIEW; SULF1 GENE; TP63 GENE; TP73 GENE; TUMOR SUPPRESSOR GENE; UBC GENE; WWOX GENE;

APOPTOSIS; CELL CYCLE; DNA DAMAGE; DNA METHYLATION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; OVARIAN NEOPLASMS;

EID: 84878190750     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2446     Document Type: Review

References (63)

1. Balch C, Huang TH, Brown R and Nephew KP: The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 191: 1552-1572, 2004. (Pubitemid 39491180)
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008. (Pubitemid 351521864)
3. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 111: 478-486, 2008.
4. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
5. Johnson SW, Ozols RF and Hamilton TC: Mechanisms of drug resistance in ovarian cancer. Cancer 71 (Suppl 2): S644-S649, 1993.
6. Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ and Tsang BK: p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 63: 7081-7088, 2003. (Pubitemid 37413443)
7. Cheng JQ, Jiang X, Fraser M, Li M, Dan HC, Sun M and Tsang BK: Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist Updat 5: 131-146, 2002. (Pubitemid 35033805)
8. Sager R: Tumor suppressor genes: the puzzle and the promise. Science 246: 1406-1412, 1989.
9. Sherr CJ: Principles of tumor suppression. Cell 116: 235-246, 2004.
10. Shanker M, Jin J, Branch CD, Miyamoto S, Grimm EA, Roth JA and Ramesh R: Tumor suppressor gene-based nanotherapy: from test tube to the clinic. J Drug Deliv 2011: 465845, 2011.
11. Kaur M, Radovanovic A, Essack M, et al: Database for exploration of functional context of genes implicated in ovarian cancer. Nucleic Acids Res 37: D820-D823, 2009.
12. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615, 2011.
13. Bast RC Jr, Hennessy B and Mills GB: The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9: 415-428, 2009.
14. Zhao M, Sun J and Zhao Z: Distinct and competitive regulatory patterns of tumor suppressor genes and oncogenes in ovarian cancer. PLoS One 7: e44175, 2012.
15. Chen H, Hardy TM and Tollefsbol TO: Epigenomics of ovarian cancer and its chemoprevention. Front Genet 2: 67, 2011.
16. Matei D, Shen C, Fang F, et al: A phase II study of decitabine and carboplatin in recurrent platinum (Pt)-resistant ovarian cancer (OC). J Clin Oncol 29 (Suppl): abst 5011, 2011.
17. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK and Zhang W: Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306: 1557-1565, 2011.
18. Zhou C, Smith JL and Liu J: Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 22: 2396-2404, 2003. (Pubitemid 36560723)
19. Borst P, Rottenberg S and Jonkers J: How do real tumors become resistant to cisplatin? Cell Cycle 7: 1353-1359, 2008. (Pubitemid 351872573)
20. Wang Y, Wiltshire T, Senft J, Reed E and Wang W: Irofulven induces replication-dependent CHK2 activation related to p53 status. Biochem Pharmacol 73: 469-480, 2007. (Pubitemid 46038851)
21. Zhang P, Gao W, Li H, Reed E and Chen F: Inducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cells. Biochem Biophys Res Commun 328: 567-572, 2005. (Pubitemid 40208348)
22. Chou JL, Su HY, Chen LY, et al: Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest 90: 414-425, 2010.
23. Plumb JA, Strathdee G, Sludden J, Kaye SB and Brown R: Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60: 6039-6044, 2000.
24. Strathdee G, MacKean MJ, Illand M and Brown R: A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18: 2335-2341, 1999. (Pubitemid 29192710)
25. Staub J, Chien J, Pan Y, et al: Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. Oncogene 26: 4969-4978, 2007. (Pubitemid 47172647)
26. Liu P, Gou M, Yi T, et al: Efficient inhibition of an intraperitoneal xenograft model of human ovarian cancer by HSulf-1 gene delivered by biodegradable cationic heparin-polyethyleneimine nanogels. Oncol Rep 27: 363-370, 2012.
27. Gopalan B, Shanker M, Scott A, Branch CD, Chada S and Ramesh R: MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity. Cancer Gene Ther 15: 1-8, 2008. (Pubitemid 350261297)
28. Xiong J, Peng ZL and Tan X: Effects of adenoviral-mediated mda-7/IL-24 gene infection on the growth and drug-resistance of drug-resistant. Sichuan Da Xue Xue Bao Yi Xue Ban 38: 433-436, 2007 (In Chinese).
29. Kawakami Y, Hama S, Hiura M, et al: Adenovirus-mediated p16 gene transfer changes the sensitivity to taxanes and Vinca alkaloids of human ovarian cancer cells. Anticancer Res 21: 2537-2545, 2001.
30. Takai N and Narahara H: Histone deacetylase inhibitor therapy in epithelial ovarian cancer. J Oncol 2010: 458431, 2010.
31. Xia X, Ma Q, Li X, et al: Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer. BMC Cancer 11: 399, 2011.
32. Materna V, Surowiak P, Markwitz E, Spaczynski M, Drag-Zalesinska M, Zabel M and Lage H: Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients. Oncol Rep 17: 505-516, 2007.
33. Cao Z, Yoon JH, Nam SW, Lee JY and Park WS: PDCD4 expression inversely correlated with miR-21 levels in gastric cancers. J Cancer Res Clin Oncol 138: 611-619, 2012.
34. Zhang X, Wang X, Song X, et al: Programmed cell death 4 enhances chemosensitivity of ovarian cancer cells by activating death receptor pathway in vitro and in vivo. Cancer Sci 101: 2163-2170, 2010.
35. Yang H, Kong W, He L, et al: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68: 425-433, 2008. (Pubitemid 351380068)
36. Lee S, Choi EJ, Jin C and Kim DH: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97: 26-34, 2005. (Pubitemid 40403670)
37. Wu H, Cao Y, Weng D, et al: Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Lett 271: 260-271, 2008.
38. Yan X, Fraser M, Qiu Q and Tsang BK: Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol Oncol 102: 348-355, 2006. (Pubitemid 44063583)
39. Kassler S, Donninger H, Birrer MJ and Clark GJ: RASSF1A and the Taxol response in ovarian cancer. Mol Biol Int 2012: 263267, 2012.
40. Chmelarova M, Krepinska E, Spacek J, Laco J, Beranek M and Palicka V: Methylation in the p53 promoter in epithelial ovarian cancer. Clin Transl Oncol 15: 160-162, 2013.
41. Reles A, Wen WH, Schmider A, et al: Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7: 2984-2997, 2001. (Pubitemid 32963815)
42. Zhang YL, Guo XR, Shen DH, Cheng YX, Liang XD, Chen YX and Wang Y: Expression and promotor methylation of p73 gene in ovarian epithelial tumors. Zhonghua Bing Li Xue Za Zhi 41: 33-38, 2012 (In Chinese).
43. Al-Bahlani S, Fraser M, Wong AY, Sayan BS, Bergeron R, Melino G and Tsang BK: P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism. Oncogene 30: 4219-4230, 2011.
44. Yang W, Cui S, Ma J, Lu Q, Kong C, Liu T and Sun Z: Cigarette smoking extract causes hypermethylation and inactivation of WWOX gene in T-24 human bladder cancer cells. Neoplasma 59: 216-223, 2012.
45. Liu YY, Li L, Li DR, Zhang W and Wang Q: Suppression of WWOX gene by RNA interference reverses platinum resistance acquired in SKOV3/SB cells. Zhonghua Fu Chan Ke Za Zhi 43: 854-858, 2008 (In Chinese).
46. Sharan R, Ulitsky I and Shamir R: Network-based prediction of protein function. Mol Syst Biol 3: 88, 2007.
47. Mostafavi S, Ray D, Warde-Farley D, Grouios C and Morris Q: GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function. Genome Biol 9 (Suppl 1): S4, 2008.
48. Huang X and Guo B: Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer Res 66: 9245-9251, 2006. (Pubitemid 44521146)
49. Ogawa T, Liggett TE, Melnikov AA, et al: Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance. Cell Cycle 11: 1656-1663, 2012.
50. Berge EO, Knappskog S, Geisler S, et al: Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers. Mol Cancer 9: 173, 2010.
51. Ramachandran K, Gordian E and Singal R: 5-azacytidine reverses drug resistance in bladder cancer cells. Anticancer Res 31: 3757-3766, 2011.
52. Ramachandran K, Miller H, Gordian E, Rocha-Lima C and Singal R: Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity. Anticancer Res 30: 3919-3925, 2010.
53. Tomkova K, Tomka M and Zajac V: Contribution of p53, p63, and p73 to the developmental diseases and cancer. Neoplasma 55: 177-181, 2008.
54. Lo Nigro C, Monteverde M, Riba M, et al: Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer. Int J Oncol 37: 1219-1228, 2010.
55. Zhang X, Gu L, Li J, et al: Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res 70: 9895-9904, 2010.
56. Poyurovsky MV, Katz C, Laptenko O, et al: The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol 17: 982-989, 2010.
57. Mir R, Tortosa A, Martinez-Soler F, et al: Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells. Int J Cancer 132: 1525-1536, 2013.
58. Kanayama H, Tanaka K, Aki M, et al: Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res 51: 6677-6685, 1991.
59. Jiang RD, Zhang LX, Yue W, et al: Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes. Ai Zheng 22: 337-345, 2003 (In Chinese).
60. Jenssen TK, Laegreid A, Komorowski J and Hovig E: A literature network of human genes for high-throughput analysis of gene expression. Nat Genet 28: 21-28, 2001. (Pubitemid 32405811)
61. Casorelli I, Bossa C and Bignami M: DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias. Int J Environ Res Public Health 9: 2636-2657, 2012.
62. Li J, Feng Q, Kim JM, et al: Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology 142: 370-380, 2001. (Pubitemid 32183698)
63. Shah MA and Schwartz GK: Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7: 2168-2181, 2001. (Pubitemid 32751613)